New Molecular Mechanism for Ullrich Congenital Muscular Dystrophy: A Heterozygous In-Frame Deletion in the COL6A1 Gene Causes a Severe Phenotype  by Pan, Te-Cheng et al.
Am. J. Hum. Genet. 73:355–369, 2003
355
New Molecular Mechanism for Ullrich Congenital Muscular Dystrophy:
A Heterozygous In-Frame Deletion in the COL6A1 Gene Causes a Severe
Phenotype
Te-Cheng Pan,1 Rui-Zhu Zhang,1 Dominick G. Sudano,3 Suely K. Marie,4
Carsten G. Bo¨nnemann,3 and Mon-Li Chu,1,2
1Department of Dermatology and Cutaneous Biology, Jefferson Institute of Molecular Medicine and 2Department of Biochemistry and
Molecular Pharmacology, Thomas Jefferson University, and 3Division of Neurology, The Children’s Hospital of Philadelphia and University
of Pennsylvania School of Medicine, Philadelphia; and 4Department of Medicine, University of Sa˜o Paulo, Brazil
Recessive mutations in two of the three collagen VI genes, COL6A2 and COL6A3, have recently been shown to
cause Ullrich congenital muscular dystrophy (UCMD), a frequently severe disorder characterized by congenital
muscle weakness with joint contractures and coexisting distal joint hyperlaxity. Dominant mutations in all three
collagen VI genes had previously been associated with the considerably milder Bethlem myopathy. Here we report
that a de novo heterozygous deletion of the COL6A1 gene can also result in a severe phenotype of classical UCMD
precluding ambulation. The internal gene deletion occurs near a minisatellite DNA sequence in intron 8 that removes
1.1 kb of genomic DNA encompassing exons 9 and 10. The resulting mutant chain contains a 33–amino acid
deletion near the amino-terminus of the triple-helical domain but preserves a unique cysteine in the triple-helical
domain important for dimer formation prior to secretion. Thus, dimer formation and secretion of abnormal
tetramers can occur and exert a strong dominant negative effect on microfibrillar assembly, leading to a loss of
normal localization of collagen VI in the basement membrane surrounding muscle fibers. Consistent with this
mechanism was our analysis of a patient with a much milder phenotype, in whom we identified a previously
described Bethlem myopathy heterozygous in-frame deletion of 18 amino acids somewhat downstream in the triple-
helical domain, a result of exon 14 skipping in the COL6A1 gene. This deletion removes the crucial cysteine, so
that dimer formation cannot occur and the abnormal molecule is not secreted, preventing the strong dominant
negative effect. Our studies provide a biochemical insight into genotype-phenotype correlations in this group of
disorders and establish that UCMD can be caused by dominantly acting mutations.
Introduction
Congenital muscular dystrophy (CMD) comprises a het-
erogeneous group of disorders characterized by muscle
weakness at birth or in early infancy (Voit 1998; Tubridy
et al. 2001; Muntoni et al. 2002a). Mutations in the ex-
tracellular matrix protein laminin a2 chain, a subunit of
laminin 2 in the muscle basement membrane, account for
a substantial proportion of CMD cases without mental
retardation. An emerging group of CMD affects O-man-
nose–linked glycosylation of a-dystroglycan, an impor-
tant laminin-2 receptor in muscle, causing a variable sec-
ondary deficiency in laminin a2 (Muntoni et al. 2002b).
Recently, another extracellular matrix protein, collagen
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type VI, has been shown to cause a distinct type of laminin
a2–positive CMD (Bertini and Pepe 2002), initially de-
scribed as “atonic-sclerotic muscular dystrophy” by Otto
Ullrich (Ullrich 1930) and now known as “CMD type
Ullrich” (MIM 254090). The signature clinical feature of
the Ullrich congenital muscular dystrophy (UCMD) phe-
notype is congenital muscle weakness with proximal joint
contractures and coexisting marked distal joint hyperlax-
ity (Nonaka et al. 1981; De Paillette et al. 1989). Cases
of variable severity have been described; however, in the
classical most severe presentation, independent walking
is not achieved or is achieved briefly and then lost, owing
to progression of weakness and contractures (Bertini and
Pepe 2002).
Collagen type VI is a ubiquitous connective tissue
component, present primarily in the stroma and also
close to the basement membrane of most tissues (Timpl
and Engel 1987; Timpl and Chu 1994). It consists of
three separate chains, the a1(VI), a2(VI) and a3(VI)
collagen chains, encoded by the COL6A1, COL6A2,
and COL6A3 genes, respectively. The a1(VI) and
a2(VI) collagen chains are similar in size (140 kDa),
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Table 1
Summary of COL6 Mutations in UCMD
Patient and Location
of Mutation Mutation Consequence Status Reference
1:
COL6A2 exon 13 Ins C Frameshift Homozygous Camacho Vanegas et al. 2001
2:
COL6A2 intron 17 2arg Del 28 bp Compound heterozygous Camacho Vanegas et al. 2001
COL6A2 intron 23 1gra Exon 24 (46 bp) skipping Compound heterozygous Camacho Vanegas et al. 2001
3a:
COL6A2 intron 17 2arg Del 28 bp Compound heterozygous Camacho Vanegas et al. 2001
4:
COL6A2 exon 18 Del 26 bp Frameshift Homozygous Higuchi et al. 2001
5:
COL6A2 intron 14 1grc Ins 53 bp or 247 bp from
intron sequence
Compound heterozygous Ishikawa et al. 2002
COL6A2 intron 23 3crg Exon 24 (46 bp) skipping Compound heterozygous Ishikawa et al. 2002
6:
COL6A3 intron 29 5arg In-frame del of 17 amino
acids in the triple-helical
domain
Homozygous Demir et al. 2002
7:
COL6A3 exon 5 Nonsense Alternatively spliced variant Homozygous Demir et al. 2002
8:
COL6A3 exon 31 Nonsense Premature termination Homozygous Demir et al. 2002
NOTE.—Ins p insertion; del p deletion.
a Only one mutation has been found in this presumably compound heterozygous patient.
and their genes are linked in a head-to-tail orientation
on chromosome 21q22.3 (Weil et al. 1988; Heiskanen
et al. 1995). The a3(VI) collagen chain is much larger
(260–330 kDa) and is encoded by the gene located on
chromosome 2q37 (Weil et al. 1988). The three chains
share the same core structure: a relatively short triple-
helical domain of 335–336 amino acids with repeating
Gly-Xaa-Yaa amino acid sequences flanked by globular
domains made up of motifs of 200 amino acids each
that are homologous to von Willebrand factor type A
(vWF A) domains (Chu et al. 1988, 1989, 1990). The
three chains fold into triple-helical monomers, which
are then assembled in an antiparallel manner into di-
mers with the N-terminal globular domains protruding
(Furthmayr et al. 1983; Chu et al. 1988). The dimers
associate laterally into tetramers, which are subse-
quently secreted into the extracellular space and as-
sociate, end-to-end, into double-beaded collagen VI
microfibrils.
Collagen VI mutations in UCMD reported to date are
exclusively recessive mutations in either the COL6A2
or COL6A3 genes (Camacho Vanegas et al. 2001; Hig-
uchi et al. 2001; Demir et al. 2002; Ishikawa et al. 2002)
(table 1), whereas dominant mutations in all three col-
lagen genes have been associated with Bethlem myopa-
thy (MIM 158810) (Jo¨bsis et al. 1996; Pan et al. 1998),
a milder childhood-onset disorder characterized by
muscle weakness and later manifesting multiple joint
contractures (Bethlem and Wijngaarden 1976). In three
families, a form of autosomal dominant limb girdle
muscular dystrophy has also been attributed to hetero-
zygous mutations in the COL6A1 and COL6A2 genes
(Scacheri et al. 2002). All of the COL6A2 mutations
described in UCMD so far lead to translational frame-
shifts and subsequent premature stop codons (Camacho
Vanegas et al. 2001; Higuchi et al. 2001; Ishikawa et
al. 2002). In two of these patients with UCMD, the
COL6A2 mRNA has been shown to be nearly absent
because of nonsense-mediated mRNA decay (Zhang et
al. 2002), resulting in a severe deficiency of collagen VI
protein in the muscle. Of the three COL6A3 homozy-
gous mutations in UCMD reported more recently, two
are nonsense mutations—one in the N-terminal glob-
ular domain and one in the triple-helical domain—and
the third one leads to skipping of an exon encoding the
triple-helical domain (Demir et al. 2002). The patients
with the COL6A3 gene mutations exhibited complete
or partial deficiency of collagen VI protein in the muscle,
but the biochemical mechanisms underlying the gene
mutations have not yet been investigated.
Here we characterized two patients affected with
CMD. One patient displays a classical, severe phenotype
of UCMD, whereas the other patient exhibits a rela-
tively milder CMD phenotype with distal joint hyper-
laxity in the absence of contractures. We show that both
patients carry de novo heterozygous in-frame deletions
of different sizes and locations in the triple-helical do-
main of the COL6A1 mRNA. We provide biochemical
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and immunohistochemical evidence for a genotype/phe-
notype correlation and show that the severe UCMD
phenotype can arise from a heterozygous mutation in
collagen VI through a dominant negative mechanism.
Subjects and Methods
Patients and Their Families
Two patients (UC-1 and UC-4) affected with CMD
associated with distal joint hyperlaxity were studied, as
were their unaffected family members. Both families
were from Brazil. Dermal fibroblast cultures were es-
tablished from skin biopsies of the patients, and genomic
DNA was extracted from peripheral blood samples from
their families. Control fibroblasts and DNA samples
were obtained from unaffected volunteers. The genetic
and clinical studies were performed in accordance with
institutional review board–approved protocols and in-
formed consent.
Cell Culture
Dermal fibroblasts were grown in Dulbecco’s modified
Eagle medium with 10% fetal bovine serum (Life Tech-
nologies) in 5% CO2 at 37C. For immunoblotting, im-
munoprecipitation, and immunofluorescence staining,
cells were cultured in the presence of 50 mg/ml L-ascorbic
acid phosphate (Wako).
Immunostaining of Fibroblasts
Fibroblasts were grown in the presence of L-ascorbic
acid phosphate until 4 d postconfluency. Cells were fixed
in 3.7% formaldehyde and were incubated at 25C with
a 1:1,000 dilution of a polyclonal antibody specific for
the a1(VI) collagen chain (antibody 1026) (Tillet et al.
1994) for 1 h. The antibody labeling reaction was de-
tected with Cy3-conjugated goat anti-rabbit IgG (1:
1,000 dilution; Jackson ImmunoResearch Laboratories),
and nuclei were counterstained with DAPI (4′,6′-diami-
dino-2-phenylindole hydrochloride). Images were ob-
tained using a Zeiss Axioskop epifluorescence micro-
scope with a Toshiba 3CCD camera.
RNA Extraction and Northern Blot Analysis
Total RNA was isolated from confluent fibroblasts
with the RNeasy Mini Kit (Qiagen). The total RNA (5
mg) was separated on a 1% agarose gel containing for-
maldehyde, was transferred to Duralon-UV membrane
(Stratagene), and was hybridized with cDNA probes la-
beled with [32P]dCTP by the Random Prime Labeling
system (Amersham Pharmacia) in Ultrasensitive Hybrid-
ization Buffer (Ambion), following protocols suggested
by the suppliers. The probes were a mixture of cDNA
clones encoding the a1(VI), a2(VI), and a3(VI) collagen
chains (clones F157, F225, and FO19) (Chu et al. 1989,
1990).
Mutational Analysis by RT-PCR and DNA Sequencing
Total RNA isolated from fibroblasts was reverse tran-
scribed using Superscript II reverse transcriptase (Life
Technologies) and oligo(dT) primer for 1 h at 42C. The
resulting cDNA was used as a template for PCR am-
plification of the entire coding regions of the COL6A1,
COL6A2, and COL6A3 mRNA transcripts (GenBank
accession numbers NM_0018489, NM_001849, and
X52022, respectively) with AmpliTaq Gold polymerase
(Applied Biosystems). The COL6A1, COL6A2, and
COL6A3 transcripts were amplified with 5, 4, and 14
primer pairs, respectively, yielding overlapping cDNA
fragments 400–1,200 bp long. The PCR conditions were
10 min at 94C; 35 cycles of 94C for 30 s, 58–60C
for 30 s, and 72C for 1 min; followed by a final ex-
tension of 72C for 7 min. PCR products were subjected
to DNA sequencing with an ABI377 DNA Sequencer
(Applied Biosystems). The primer pairs revealing the
COL6A1 deletions were as follows: forward, 5′-AACG-
TTGAGCAAGTGTGCTG-3′; and reverse, 5′-TTCACC-
AGGGTCTCCTCTTG-3′.
Characterization of the COL6A1 Gene Mutations
Genomic DNA isolated from patient UC-1 and his
family was PCR amplified with a forward primer in in-
tron 6 (5′-GACTCGTCTCCATGCTTTCC-3′) and a re-
verse primer in intron 11 (5′-CATGGGGACTGACAGT-
GATG-3′), through use of the Expand Long Template
PCR system (Roche). The PCR conditions were 94C for
2 min; 30 cycles at 94C for 10 s, 58C for 30 s, and
68C for 8 min; followed by a final extension at 68C
for 7 min. The PCR products were analyzed on 1%
agarose gels. PCR products yielded from patient UC-1
were cloned into the pCR-TOPO vector (TOPO TA
Cloning Kit; Invitrogen) and were subjected to DNA
sequencing.
Genomic DNA isolated from patient UC-4 and his fam-
ily was PCR amplified with a forward primer located in
the boundary of exon 12/intron 12 (5′-AGGGCTACAA-
GGTGAGCGTG-3′) and a reverse primer in intron 15 (5′-
CAGGACTTGCTTCCAGGAGA-3′), through use of
AmpliTaq Gold polymerase (Applied Biosystems) and
the cycling conditions described above for RT-PCR. The
PCR products from UC-4 and his family were subjected
to DNA sequencing.
Protein Analysis by Immunoblotting
and Immunoprecipitation
Immunoblot analysis of culture medium and cell lay-
ers from confluent fibroblasts were performed using
1026 antibody specific for the a1(VI) collagen chain (Til-
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let et al. 1994), as described elsewhere (Pepe et al. 1999;
Camacho Vanegas et al. 2002). For immunoprecipita-
tion of collagen VI protein, confluent fibroblasts were
metabolically labeled with [35S]cysteine overnight and
were precipitated with 1014 antibody specific for the
a3(VI) collagen chain (Specks et al. 1992), as described
elsewhere (Camacho Vanegas et al. 2001). Samples were
electrophoresed on 3%–8% SDS-polyacrylamide gels
under reduced conditions (25 mM dithiothreitol [DTT])
or on composite 0.5% agarose, 2.4% polyacrylamide
gels without reduction with DTT (Lamande´ et al. 1998).
Reduced (230 and 400 kDa) and unreduced (900 kDa)
forms of laminin were used as the molecular mass stan-
dard on the composite gel.
Immunostaining of Muscle Biopsies
Biopsies were cut in 10-mm sections through use of a
Microm HM505E cryostat and were mounted onto mi-
croscope slides before being stored at 80C until fur-
ther use. After allowing the slides to acclimate to room
temperature, they were fixed with methanol at room
temperature for 20 s and were briefly washed with ice-
cold 1# PBS (0.01 M KH2PO4, 0.1 M Na2HPO4, 1.37
M NaCl, 0.027 M KCl, pH 7.4). The sections were
preincubated in vehicle (10% fetal bovine serum, 1#
PBS, 0.1% Triton X-100) at room temperature for 1 h.
Primary antibodies at the appropriate dilution in vehicle
were applied to the sections and allowed to incubate
overnight at 4C. A mouse monoclonal antibody rec-
ognizing collagen type VI (MAB3303; 1:2,500) was ob-
tained from Chemicon International. The rabbit poly-
clonal antibody against perlecan domain III (1030; 1:
2,000) was graciously provided by R. Timpl of the Max
Planck Institute for Biochemistry, Germany. Slides were
washed in 1# PBS (3 # 20 min) prior to applying the
secondary antibodies in vehicle at room temperature for
1 h in the dark. Alexa Fluor 488–conjugated goat anti-
mouse IgG and Alexa Fluor 568–conjugated goat anti-
rabbit IgG (Molecular Probes) were used as secondary
antibodies at 1:500 dilution. The slides were washed in
1# PBS and were post-fixed at room temperature for 8
min in the dark, using cold methanol (25C). The slides
were briefly washed with 1# PBS before being cover-
slipped with either Vectashield or Biomedia Gel/Mount
media mount.
Images were obtained on a Leica Inverted DM IRE2
HC fluo TCS 1-B-UV microscope coupled to a TCS SP2
spectral confocal system/UV with a scan head containing
an AOBS acousto-optical tunable filter. The green HeNe
(543 nm/1.2 mW) and blue argon (488 nm/20 mW) laser
lines were used to visualize the fluorophores. The images
were captured at 1,024#1,024 resolution under a 40#
oil lens.
Results
Patients UC-1 and UC-4 Display Severe and Mild
Symptoms of CMD, Respectively
Patient UC-1, age 12 years, had congenital-onset mus-
cular hypotonia and weakness, followed by severely de-
layed motor development. He never stood or walked
without support, and his maximal motor ability was
sitting without support. He was first evaluated by us at
age 6 years, when he presented with severe muscular
hypotonia and weakness. The muscle weakness was
graded as 3/5 MRC (Medical Research Council) prox-
imally and distally, with minimal bilateral facial weak-
ness. There was marked generalized muscle atrophy. The
tendon reflexes were absent or depressed. Severe joint
contractures were prevalent, affecting preferentially
proximal but also distal joints in the finger flexors of
the hands while maintaining small joint hyperlaxity at
the same time. He had protruding calcanei. His cognitive
development had been completely normal. Since age 11
years, he had suffered from respiratory insufficiency, ne-
cessitating ventilatory assistance. His creatine kinase
(CK) level was normal, and electromyography (EMG)
results were interpreted as showing a myopathic pattern.
Results of a CT scan of the brain, cardiac evaluation,
and ophthalmological evaluation were all normal. A
muscle biopsy, which had been obtained at age 9 years
5 mo, showed moderate proliferation of endomysial and
perimysial connective tissue and variation of muscle fiber
diameter, as well as scattered degenerating fibers. Patient
UC-1 thus displays a classical severe UCMD phenotype.
Patient UC-4, age 6 years, also presented with hy-
potonia since birth. However, he was able to walk since
age 1 year and able to climb stairs, but he got up from
the floor with a Gowers’ maneuver and suffered frequent
falls. Muscle weakness was moderate, at ∼4/5 MRC,
with some proximal predominance. The patient had gen-
eralized hyperextensibility of his joints in the upper and
lower extremities, in particular in the small joints. There
were slight asymmetric contractures of the Achilles ten-
dons, but no other contractures were found. CK level
was normal. EMG demonstrated a myopathic pattern,
and muscle biopsy exhibited a mildly dystrophic pattern,
with variation in muscle fiber diameter, moderate in-
crease in endomysial connective tissue, and occasional
degenerating fibers.
Collagen VI Microfibrils Are Absent in Fibroblasts
from UC-1 and Markedly Reduced in Fibroblasts
from UC-4
Fibroblasts from patients UC-1 and UC-4 were im-
munostained with an antibody specific to the a1(VI)
collagen chain. Whereas the control fibroblasts exhibited
an extensive collagen VI microfibrillar network in the
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Figure 1 Deposition of collagen VI microfibrils in the extracellular matrix of dermal fibroblasts. Fibroblasts from an unaffected control
individual (A and B), patient UC-1 (C and D), and patient UC-4 (E and F) were grown in the presence of 50 mg/ml L-ascorbic acid phosphate
for 4 d postconfluency and were stained with the a1(VI) collagen-specific antibody. The antibody reaction was detected with Cy3-conjugated
goat anti-rabbit IgG (red), and cells were counterstained with DAPI (blue) to visualize nuclei. Original magnifications #20 (A, C, and E) and
#40 (B, D, and F).
extracellular matrix, fibroblasts from UC-1 were found
to deposit few, if any, collagen VI microfibrils (fig. 1).
In contrast, fibroblasts from UC-4 deposited collagen VI
microfibrils in markedly reduced amounts as compared
with the control fibroblasts. Similar immunostaining re-
sults were observed when the a3(VI) collagen chain–
specific 1014 antibody was used (data not shown).
The fibroblasts from both UC-1 and UC-4 deposited
amounts of type I collagen fibrils similar to that depos-
ited by the control fibroblasts (data not shown). The
results suggested that both patients might carry collagen
VI mutations.
The COL6A1 Transcripts in UC-1 and UC-4 Each
Contain a Heterozygous In-Frame Deletion
within the Triple-Helical Domain
To search for possible collagen VI mutations in UC-
1 and UC-4, the coding regions of the COL6A1,
COL6A2, and COL6A3 mRNA transcripts were am-
plified from fibroblast RNA by RT-PCR. A primer pair
flanking the COL6A1 triple-helical coding region am-
plified two products of equal intensity in both patients,
one of which was the expected size, whereas the other
one was slightly smaller (data not shown). DNA se-
quencing revealed that the shorter product from UC-1
contained a deletion of 99 bp, extending from nucleotide
805 to 903, encoded by exons 9 (54 bp) and 10 (45 bp)
of the COL6A1 gene (fig. 2). The shorter product from
UC-4 harbored a smaller deletion, of 54 bp, that was
located farther downstream and corresponded to nucle-
otides 1003–1056, encoded by exon 14. DNA sequences
of the larger PCR products from both patients showed
no deviations from the reference COL6A1 cDNA se-
quence. The results indicated that UC-1 and UC-4 carry
heterozygous COL6A1 in-frame deletions of different
sizes located at different positions within the triple-hel-
ical domain.
Because all previously reported patients with UCMD
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Figure 2 In-frame deletions in the triple-helical domain of the COL6A1 mRNA in patients UC-1 and UC-4. A and B, DNA sequence
chromatograms showing a deletion of 99 bp encoded by exons 9 and 10 in UC-1 (A) and a deletion of 54 bp encoded by exon 14 in UC-4
(B). DNA and amino acid sequences of the normal and mutant COL6A1 mRNA surrounding the mutations are shown. Arrowheads mark
exon borders. C, Schematic diagram of normal and mutant a1(VI) collagen chains. The normal a1(VI) collagen chain consists of a triple-helical
domain (TH) of 336 amino acids flanked by N- and C-terminal globular domains made up of vWF-A–like motifs (N1, C1, and C2). The TH
domain contains a single cysteine residue (depicted as “C”) at position 89, which is important for dimer assembly. Patient UC-1 contains a
33–amino acid deletion near the N-terminus of the triple-helical domain, whereas patient UC-4 contains an 18–amino acid deletion somewhat
downstream, which removes the cysteine residue.
carry homozygous or double heterozygous mutations, it
was possible that a second mutation in one of the col-
lagen VI genes could be present in UC-1 and UC-4 in a
compound heterozygous state with the identified mu-
tations. Therefore, the entire coding regions of the
COL6A1, COL6A2, and COL6A3 transcripts were an-
alyzed by DNA sequencing. The analyses yielded a num-
ber of silent nucleotide polymorphisms and single-nu-
cleotide changes that resulted in amino acid substitutions
(table 2). All of the amino acid substitutions were found
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Table 2
Polymorphisms in Collagen VI Genes That Result in Amino Acid
Changes
Patient, Gene,
and Exon
Nucleotide
Change
Amino Acid
Change Status
UC-1:
COL6A1:
35 2669CrT S889L Heterozygous
COL6A2:
26 2039ArG H680R Heterozygous
28 2803GrA G935R Heterozygous
COL6A3:
25 6653CrT P2218L Heterozygous
28 6860CrG P2287R Homozygous
41 9203CrT T3068I Homozygous
UC-4:
COL6A2:
18 1466GrA R489Q Heterozygous
26 2039ArG H680R Homozygous
COL6A3:
4 872GrA R291K Heterozygous
36 7292TrA V2431D Homozygous
39 8491GrC D2831T Homozygous
40 8780CrT T2927M Heterozygous
40 8870-8871insTGC 2957insA Homozygous
40 8959GrA V2987M Homozygous
41 9203CrT T3068I Heterozygous
in genomic DNA from control individuals and thus were
not pathological mutations.
An Internal COL6A1 Gene Deletion in UC-1 Removes
Exons 9 and 10, Whereas a Splice Donor Site
Mutation in UC-4 Results in Skipping of Exon 14
To delineate the mRNA mutations at the genomic level
and determine whether the mutations were inherited,
genomic DNA from the patients and their families was
PCR amplified and DNA sequenced. Primers in introns
6 and 11 were used to amplify genomic DNA from UC-
1 and his family (parents, elder brother, and sister) (fig.
3A). The genomic region was found to be highly variable
in length, since two major PCR products, ranging in size
from 2.6 to 3.2 kb, were amplified from DNA of the
family members and unaffected controls (fig. 3B). The
size variation was due to the presence of a minisatellite
near the 5′ end of intron 8. In the reference sequence
(GenBank accession number NT_011515), the minisa-
tellite consists of 32 tandem repeats of the sequence ccag-
atggagggga(t/c)ggcggg(a)gt. In UC-1, a 2.6-kb PCR
product and a substantially smaller 1.8-kb fragment
were obtained. DNA sequencing indicated that the 1.8-
kb DNA fragment contained a deletion of 1,095 bp that
removed the genomic region encompassing exons 9 and
10 and the intervening intron (fig. 3A). The proximal
deletion breakpoint was located in intron 8 at 17 bp
downstream of the last repeat in the minisatellite se-
quence (fig. 3C). The distal breakpoint was in intron 10
at 5 bp downstream of exon 10. At the distal breakpoint,
a 15-bp inserted sequence (tccctccccatttcc) was found,
of which the sequence tccccatttcc was a direct duplica-
tion of adjacent intron 10 sequence. The DNA sequence
of the 2.6-kb fragment corresponded well with the ref-
erence COL6A1 genomic sequence. Comparison of the
sizes of the PCR products from UC-1 and his family
indicated that the genomic deletion in UC-1 was not
present in his parents and two siblings (fig. 3B) and,
hence, had arisen de novo. It also indicated that the
normal 2.6-kb COL6A1 allele in UC-1 was inherited
from the father; therefore, the novel genomic deletion
in UC-1 had occurred on his maternal COL6A1 allele.
Genomic DNA from UC-4 and his family (parents,
elder brother and sister) was PCR amplified with a
primer pair flanking exon 14, which yielded a single PCR
product of 854 bp in all family members. DNA sequenc-
ing of the fragments showed a heterozygous GrA tran-
sition at 1 position of the splice donor site in intron
14 in UC-4 (fig. 3A). The mutation was not found in
his parents and siblings and therefore also had arisen de
novo.
Mutant a1(VI) Collagen Chain Is Secreted
Extracellularly in UC-1 but Not in UC-4
The effects of the COL6A1 gene mutations on col-
lagen VI mRNA and protein synthesis were studied.
Analysis of total RNA from UC-1 and UC-4 fibroblasts
by northern blot hybridization showed that the steady-
state levels of collagen VI mRNA for all three chains in
UC-1 and UC-4 were comparable to those in the control
(fig. 4A). The results suggest that the mutations do not
significantly affect transcription and stability of the
COL6A1 mRNA, unlike previous findings of other pa-
tients with UCMD (Zhang et al. 2002).
To assess the synthesis and secretion of the mutant
a1(VI) collagen chains in fibroblasts from UC-1 and UC-
4, cell layers and culture media were analyzed by im-
munoblotting using the antibody specific for the a1(VI)
collagen chain. In the cell layers of UC-1 and UC-4,
approximately equal amounts of normal and shorter
a1(VI) collagen chains were observed (fig. 4B, lanes
1–3), indicating that the mutant chains in both patients
were synthesized efficiently and were stable. Because of
posttranslational modifications, the a1(VI) collagen
chains that were secreted extracellularly migrated more
slowly than those found in the cell layers. Both normal
and shorter chains could be detected in the medium of
UC-1, whereas only the normal chain was seen in the
medium of UC-4. Quantification of three separate im-
munoblots with a densitometer revealed that the amount
of mutant chain secreted by the fibroblasts from UC-1
was 53% of the normal counterpart.
Fibroblasts from UC-1 and UC-4 were metabolically
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Figure 3 Mutational analysis of the COL6A1 gene. A, Schematic diagram of the COL6A1 genomic region including exons 7–15 (blackened
boxes). Exon 8 encodes the beginning of the triple-helical domain, and exons 9–15 each encode discrete numbers of Gly-Xaa-Yaa repeats in
the triple-helical domain. A minisatellite (unblackened box labeled “VNTR”) is present at the 5′ end of intron 8. In patient UC-1, one of the
COL6A1 alleles contains a 1.1-kb gene deletion (dotted box) extending from intron 8 to intron 10. Patient UC-4 carries a heterozygous GrA
transition at the 1 position of intron 14. B, PCR amplification of genomic DNA from patient UC-1 and his family (lanes 2–6) and from four
unaffected control individuals (lanes 7–10) with primers in introns 6 and 12 (arrows in A). Lanes 1 and 11 contain DNA size markers. C, DNA
sequence of the 1.8-kb PCR product from UC-1, showing the breakpoint of the internal gene deletion (middle line) and its alignment with the
normal COL6A1 genomic sequence of intron 8 (top line) and of intron 9–exon 10–intron 10 (bottom line). Exon sequences are in capital
letters. Between the arrows are 15-bp inserted sequences in the deletion junction, which contains an 11-bp direct duplication of the sequence
in intron 10 (boxed). The dotted box depicts the last repeat of the minisatellite sequence in intron 8. In p intron; Ex p exon.
labeled with [35S]cysteine and were immunoprecipitated
with the antibody against the a3(VI) collagen chain. The
antibody would precipitate free a3(VI) collagen chain
as well as a1(VI) and a2(VI) collagen chains that are
folded together with the a3(VI) collagen chain in a triple
helix. In the cell layers of fibroblasts from both UC-1
and UC-4, the antibody precipitated both the normal
and shorter a1(VI) collagen chains (fig. 4C), indicating
that the mutant chains from both patients were able to
incorporate into triple helices. As predicted from the
sizes of the deletions, the mutant chain in UC-1 migrated
faster than that in UC-4. In contrast, the mutant a1(VI)
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Figure 4 Analysis of collagen VI mRNA and protein in fibroblasts from UC-1 and UC-4. A, Northern blot analysis of total RNA (5 mg)
from normal fibroblasts and those from UC-1 and UC-4, with a mixture of [32P]dCTP-labeled cDNA probes for the three collagen VI mRNA.
The probes hybridized with the a1(VI), a2(VI), and a3(VI) collagen mRNA of 4.2, 3.5, and 9–10 kb, respectively, plus an alternatively spliced
a2(VI) collagen mRNA, a2(VI)a, of 6.0 kb. B, Immunoblot analysis of cell layer extracts (lanes 1–3) and culture media (lanes 4–6) from normal
fibroblasts (lanes 1 and 4) and those from UC-1 (lanes 2 and 5) and UC-4 (lanes 3 and 6), with the antibody specific for the a1(VI) collagen
chain. Lanes 1–3 contain 10 mg of total protein from the cell layers, and lanes 4–6 contain 100 ml of culture medium precipitated with 0.9 ml
of 100% EtOH. C–E, Immunoprecipitation of cell layers (C) and culture media (D, E) from normal fibroblasts (lane 1) and those from UC-1
(lane 2) and UC-4 (lane 3), with the antibody specific for the a3(VI) collagen chain. Fibroblasts were labeled with [35S]cysteine overnight.
Samples in B, C, and D were reduced with 25 mM DTT and separated on 3%–8% polyacrylamide gels. Samples in E were separated on a
composite agarose polyacrylamide gel in the absence of 25 mM DTT. The mutant a1(VI) collagen chains are depicted as a1(VI)m. The arrow
indicates a protein present in higher amounts in fibroblasts from UC-1 compared with the normal control fibroblasts.
collagen chains could be detected only in the medium
of UC-1 but not of UC-4 (fig. 4D), consistent with the
results of the immunoblot analysis above.
To determine whether the shorter a1(VI) collagen
chains secreted by fibroblasts from UC-1 were present
in dimers and tetramers, the immunoprecipitated ma-
terial was analyzed on a composite agarose/polyacryl-
amide gel without reduction using DTT. The majority
of the secreted collagen VI chains in UC-1 were found
in tetramers similar to the normal control fibroblasts (fig.
4E). This implied that the mutant a1(VI) collagen chain
secreted extracellularly was most likely incorporated
into the tetramers. It was noted that there were fewer
monomers in UC-1 than in the control, whereas a pro-
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tein complex that migrated below the monomers was
present in higher amounts in UC-1 as compared with
the control. This was a consistent finding in two separate
experiments. The nature of this faster-migrating protein
band is unclear; its apparent molecular mass appears
larger than that of a mutant monomer containing a
shorter a1(VI) collagen chain.
Collagen VI Protein Is Aberrantly Localized
in the UC-1 Muscle but Reduced in the UC-4 Muscle
Muscle biopsies from UC-1 and UC-4 were immu-
nostained with antibodies against collagen VI and per-
lecan simultaneously (fig. 5). In normal muscle, collagen
VI colocalized with perlecan in the basement membrane
surrounding muscle fibers. In the UC-1 muscle, collagen
VI protein was not seen in the basement membrane, even
though the basement membrane appeared intact, as
shown by the uniform perlecan staining. Abundant col-
lagen VI protein, however, was found in the interstitial
and perivascular regions between muscle fibers. In con-
trast, some collagen VI protein was present in the base-
ment membrane of the UC-4 muscle, but at a markedly
reduced level relative to the staining with the perlecan
antibody.
Discussion
Here we demonstrate that a patient affected with the
severe phenotype of UCMD (UC-1) carries a heterozy-
gous in-frame deletion in the COL6A1 gene but no
additional mutations in the COL6A1, COL6A2, and
COL6A3 genes. The gene deletion is not present in the
unaffected family members and has arisen de novo. The
findings indicate that the heterozygous COL6A1 gene
deletion is the underlying cause of the severe UCMD
phenotype in this patient.
The deletion in UC-1 is located very close to the min-
isatellite in intron 8 of the COL6A1 gene, suggesting a
role for the minisatellite sequence in the gene deletion.
PCR analysis of the COL6A1 minisatellite alleles in the
UC-1 family and 15 unaffected control individuals in-
dicates that the length of this minisatellite varies greatly
(fig. 3B and data not shown). This result supports pre-
vious findings that minisatellites can be found in the
vicinity of recurrent translocation breakpoints and con-
stitute chromosomal fragile sites (Vergnaud and Den-
oeud 2000). Minisatellites have, in addition, been
shown to affect transcription and intron splicing (Ken-
nedy et al. 1995; Turri et al. 1995). For instance, an
expansion of an intronic minisatellite in the USH1C
gene has been correlated with the Usher syndrome type
1C in the Acadian population (Verpy et al. 2000). It
remains to be tested whether the variation in the size
of the minisatellite in intron 8 of the COL6A1 gene
interferes with intron splicing and/or affects the steady-
state mRNA level.
The milder CMD phenotype of patient UC-4 is caused
by a heterozygous skipping of exon 14 in the COL6A1
transcript. This is a recurring mutation in the COL6A1
gene, since skipping of exon 14 has previously been
found in two unrelated patients with Bethlem myopathy
resulting from mutations in either the first or second
nucleotide of the splice donor site in intron 14 (Lamande´
et al. 1999; Pepe et al. 1999). Patient UC-4 does not
display the significant joint contractures characteristic
of patients with Bethlem myopathy at this time. How-
ever, he is still young and may develop contractures in
the future; therefore, his phenotype at this age could
well be compatible with sporadic Bethlem myopathy. It
has been pointed out that Bethlem myopathy may pres-
ent as a mild congenital muscular dystrophy (Jo¨bsis et
al. 1999).
The deletion in UC-1 removes 11 contiguous Gly-
Xaa-Yaa repeats in the a1(VI) collagen chain very close
to the N-terminus of the triple-helical domain (amino
acids 13–45 of the triple-helical domain). On the other
hand, UC-4 contains a smaller deletion of six Gly-Xaa-
Yaa repeats at amino acids 79–96, which is also located
at the N-terminal portion of the triple-helical domain,
but somewhat downstream. For fibrillar collagens, the
triple-helical folding starts from the C-terminal non-
collagenous domains and propagates in a zipperlike
fashion toward the N-terminus (Bachinger et al. 1981;
Engel and Prockop 1991). If we assume that this is also
the case for collagen VI, deletions in the N-terminal
portion of the triple-helical domain such as those found
in UC-1 and UC-4 would not prevent the mutant chains
from folding into a triple helix. Indeed, immunoprecip-
itation of the cell layers from the fibroblasts of UC-1
and UC-4 indicates that the shorter a1(VI) collagen
chains in both patients are incorporated into triple-hel-
ical monomers (fig. 4C). The mutant monomers pre-
sumably would contain shorter triple-helical domains,
because the deletions in the mutant chain are likely to
be accommodated by looping out the corresponding
regions of the normal chains in a manner similar to a
triple-helical deletion in type II collagen described else-
where (Weis et al. 1998).
The two different deletions, however, have distinct
effects on the subsequent step of collagen VI supra-
molecular assembly. Unlike most collagens, the triple-
helical collagen VI monomers are assembled into dimers
and tetramers prior to secretion into the extracellular
space (fig. 6A) (Timpl and Engel 1987; Timpl and Chu
1994). Dimers are formed by the antiparallel, staggered
assembly of two monomers, and the single cysteine lo-
cated at amino acid 89 of the triple-helical domains in
the a1(VI) or a2(VI) collagen chains is responsible for
the assembly/stability of the dimers (Furthmayr et al.
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Figure 5 Immunostaining of muscle biopsies from UC-1, UC-4, and an unaffected control individual. Sections were stained with the
monoclonal antibody against collagen VI (green in A, D, and G) and the polyclonal antibody against perlecan (red in B, E, and H). C, F, and
I show a merge of green and red fluorescence. In normal muscle (A, B, and C), collagen VI and perlecan colocalize in the basement membrane.
In the muscle from UC-1 (D, E, and F), collagen VI is absent in the basement membrane surrounding muscle fibers; instead, it is accumulated
in the interstitial and perivascular space between muscle fibers. In the muscle from UC-4 (G, H, and I), collagen VI is present in the basement
membrane but appears patchy and significantly reduced relative to the perlecan staining. Collagen VI staining is increased in the interstitial and
perivascular space.
1983; Chu et al. 1988). Tetramers are assembled by the
lateral association of two dimers, whereby the single
cysteine residue at amino acid 50 in the triple-helical
domain of the a3(VI) collagen chain is involved in tet-
ramer formation/stability. The critical regions involved
in dimer and tetramer formation are all retained in the
mutant chain of UC-1; thus, the mutant chain should
be able to assemble into dimers and tetramers and be
secreted. By contrast, cysteine 89 is deleted in the mu-
tant chain of UC-4, which would prevent the abnormal
monomer from assembling into dimers. Consequently,
only normal dimers and tetramers will be formed.
The immunoprecipitation and immunoblot analyses
indeed confirm that the shorter a1(VI) collagen chain
in UC-1 is incorporated into tetramers and secreted (fig.
4B, 4D, and 4E). Theoretically, equal amounts of the
normal and mutant chains synthesized by UC-1 would
result in assembly of equal amounts of the normal and
mutant monomers. However, because the mutant chain
can be incorporated in the subsequent assembly steps,
Figure 6 Schematic diagram showing the effects of two different internal deletions on collagen VI assembly. A, Intracellular events. Normally
(left), the a1(VI), a2(VI), and a3(VI) collagen chains presumably fold from the C-terminal end into a triple-helical monomer. Two key cysteine
residues (vertical lines) in the N-terminal portion of the triple helix are critical for subsequent supramolecular assembly. Dimers are formed by the
staggered antiparallel association of monomers with the N-terminal globular domains protruding at both ends. The outer cysteines contributed by
either the a1(VI) or a2(VI) collagen chains are important for the dimer assembly. The dimers associate laterally into tetramers, which are stabilized
by the outer cysteines contributed by the a3(VI) collagen chain. In UC-1 (middle) and UC-4 (right), equal amounts of normal and mutant (gray)
a1(VI) collagen chains assemble into equal amounts of normal and mutant monomers. Because the cysteines critical for dimer and tetramer formation
are preserved in UC-1, both normal and mutant monomers can assemble into dimers and tetramers in any combination. Thus, only 1/4 of the
dimers and 1/16 of the tetramers are entirely composed of normal chains, whereas 15/16 of the tetramers contain a mixture of normal and mutant
chains (gray striped lines). The deletion in UC-4 removes the cysteine in the triple-helical domain of the a1(VI) collagen chain, which prevents the
abnormal monomers from assembling into dimers. Therefore, only normal tetramers are formed and secreted. The mutant chain in UC-4 may
interfere with the assembly of the normal dimers, resulting in the formation and secretion of normal tetramers at a level 1/2 that of the control.
B, Extracellular event. Normally, tetramers are secreted and associated end-to-end into double-beaded microfibrils (top). The microfibrillar assembly
involves interactions of the N- and C-globular domains and triple-helical domain. The deletion in UC-1 is located very close to the N-terminal end
of the triple-helical domain (broken thick lines). Presumably, the triple helix in the mutant monomer is shortened because the normal a2(VI) and
a3(VI) collagen chains are looped out at the region corresponding to the deletion (bottom). As a result, the mutant tetramers cannot properly align
with normal tetramers to form the double-beaded structure. Because the majority of the secreted tetramers are abnormal, long microfibrils cannot
be assembled.
Pan et al.: Heterozygous COL6A1 Deletion Causes UCMD 367
the effect of the mutation would be greatly amplified.
It is expected that only 1/4 of the dimers and only 1/
16 of the tetramers would be entirely composed of nor-
mal chains, whereas 15/16 of the tetramers would be
abnormal, with 1–4 mutant chains (fig. 6A). Experi-
mentally, however, it appears that certain types of ab-
normal tetramers may not be formed and/or secreted,
because immunoblot analysis shows that only 53% of
the shorter a1(VI) collagen chains are secreted (fig. 4B).
The effect of the deletion likely is further amplified in
the microfibrillar assembly step after the mutant tet-
ramers are secreted. Since microfibrils are assembled by
end-to-end association of the tetramers via the N-ter-
minus, mutant tetramers with structurally abnormal N-
termini cannot correctly align with their neighboring
tetramers and thus would drastically impair microfi-
brillar assembly (fig. 6B).
In contrast, the shorter a1(VI) collagen chain in UC-
4 cannot be detected in the culture medium under dif-
ferent electrophoretic conditions (fig. 4 and data not
shown). This observation is consistent with previous
findings in the two patients with Bethlem myopathy
who had the same deletion (Lamande´ et al. 1999; Pepe
et al. 1999). However, it should be noted that, owing
to posttranslational modifications of the secreted chains
and relatively small size of the deletion, the possibility
remains that the mutant chain may be secreted but can-
not be distinguished from the normal chain experimen-
tally. The mutant chain may, in addition, form a par-
tially assembled dimer with its normal counterpart
intracellularly (fig. 6). In either case, the mutant chain
might exert a slight dominant negative effect. Therefore,
the deletion in UC-4 would lead to assembly of collagen
VI microfibrils at a level 50% that of the control.
It is interesting to consider another in-frame deletion
in the triple helical domain reported in a patient with
UCMD (table 1). This patient carried a homozygous
splice mutation in the COL6A3 gene, causing skipping
of exon 29 and an in-frame deletion of 51 amino acids
in the C-terminus of the triple-helical domain (Demir
et al. 2002). However, the heterozygous parents were
not affected, suggesting that the mutation does not act
in a dominant negative fashion. Studies using intro-
duced triple-helical deletions as well as glycine substi-
tutions in the a3(VI) collagen chain have shown that
the biosynthetic consequences of the mutations depend
on their positions in the triple-helical domain (Lamande´
et al. 1999, 2002). Whether the mutant a3(VI) collagen
chain with the C-terminal triple-helical deletion is in-
corporated into the triple helix to potentially act in a
dominant negative way remains an interesting question.
The distinct effects of these two triple-helical dele-
tions on collagen VI supramolecular assembly are sup-
ported by immunofluorescent labeling of fibroblasts,
showing an almost complete absence of collagen VI
microfibrils in the fibroblasts of UC-1 and a significant
reduction in the fibroblasts of UC-4 (fig. 1). The dif-
ferential effects are also reflected in their muscle bi-
opsies, which display an absence and substantial re-
duction of collagen VI immunostaining in the muscle
basement membrane of UC-1 and UC-4, respectively
(fig. 5). This correlates well with the clinical severity
of these two patients. The substantial reduction in col-
lagen VI immunofluorescence observed in fibroblasts
and muscle biopsy from UC-4 compared with the con-
trol suggests that the mutant chain in UC-4 may exert
a slight dominant negative effect, either intracellularly
or extracellularly.
Of particular interest is the observation that the mu-
tation in UC-1 leads to loss or mislocalization of col-
lagen VI protein in the muscle basement membrane
(fig. 5). By immunoelectron microscopy, collagen VI
filaments have previously been shown to localize in
close juxtaposition to the muscle basement membrane
(Kuo et al. 1997). The results from the muscle of UC-
1 suggests that only the assembled collagen VI mi-
crofibrils can be properly anchored to the basement
membrane. It also suggests that the substantial
amounts of mutant collagen VI tetramers secreted into
the extracellular space are not degraded but instead
are aberrantly accumulated in the interstitial and peri-
vascular space. It is not clear what molecule anchors
the collagen VI network to the basement membrane.
Possible candidates include collagen type IV, perlecan,
and fibronectin, all of which are present in the base-
ment membrane and interact with collagen VI in vitro
(Tillet et al. 1994; Kuo et al. 1997). The results high-
light the critical role of collagen VI in the muscle base-
ment membrane and suggest that mislocalization of
collagen VI is a potential pathological mechanism for
the severe UCMD phenotype.
Mutations in collagen type VI have now been asso-
ciated with seemingly distinct types of muscular dystro-
phy, which vary widely in clinical severity and connective
tissue involvement. Previously, heterozygous mutations
are found in the milder phenotypes of Bethlem myopathy
and a form of dominant limb girdle muscular dystrophy,
whereas homozygous or double heterozygous mutations
are observed in the severe phenotype of UCMD. The
identification of a heterozygous mutation in a severe phe-
notype of UCMD thus is a significant departure from
previous observations. However, this finding should not
be entirely unexpected, because heterozygous mutations
in the triple-helical domain of collagen genes are known
to cause severe or even lethal phenotypes owing to dom-
inant negative effects (procollagen suicide) exerted by
structurally defective chains (Prockop 1990; Myllyharju
and Kivirikko 2001).
In conclusion, we have established the COL6A1 gene
as the third locus for UCMD and, furthermore, have
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identified the first example of a multiexon deletion in
collagen VI genes. We have also provided evidence that
a heterozygous mutation in collagen VI can cause a
severe UCMD phenotype through a dominant negative
mechanism and suggested a correlation between mu-
tation location and clinical severity. This finding also
has considerable relevance for genetic counseling in
UCMD.
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